Cargando…

Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma

BACKGROUND: Glioblastoma is a disease with high heterogeneity that has long been difficult for doctors to identify and treat. ARHI is a remarkable tumor suppressor gene in human ovarian cancer and many other cancers. We found over-expression of ARHI can also inhibit cancer cell proliferation, decrea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Chen, Shu, Mengting, Ye, Junyi, Wang, Xiaoxiong, Chen, Xin, Liu, Zhendong, Zhao, Wenyang, Zhao, Boxian, Zheng, Zhixing, Yin, Zhiqin, Gao, Ming, Zhao, Haiqi, Wang, Kaikai, Zhao, Shiguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515631/ https://www.ncbi.nlm.nih.gov/pubmed/31088402 http://dx.doi.org/10.1186/s12885-019-5643-z

Ejemplares similares

Nitazoxanide, an antiprotozoal drug, inhibits late-stage autophagy and promotes ING1-induced cell cycle arrest in glioblastoma
por: Wang, Xiaoxiong, et al.
Publicado: (2018)

Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling
por: Okoye, Isobel, et al.
Publicado: (2017)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

The expression of aplysia ras homolog I (ARHI) and its inhibitory effect on cell biological behavior in esophageal squamous cell carcinoma
por: Mao, Yuqiang, et al.
Publicado: (2017)

Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
por: Augsten, Martin, et al.
Publicado: (2014)

MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1
por: Brundage, Meghan E., et al.
Publicado: (2014)

Transforming ras oncogenes and multistage carcinogenesis.
por: Balmain, A.
Publicado: (1985)

Ras oncogene mutation in multiple myeloma
Publicado: (1989)

RAS: Striking at the Core of the Oncogenic Circuitry
por: Gimple, Ryan C., et al.
Publicado: (2019)

Oncogenic Ras suppresses ING4-TDG-Fas axis to promote apoptosis resistance
por: Sun, Jie, et al.
Publicado: (2015)

Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
por: Jeng, Hao-Hsuan, et al.
Publicado: (2012)

Role of mTOR, Bad, and Survivin in RasGAP Fragment N-Mediated Cell Protection
por: Peltzer, Nieves, et al.
Publicado: (2013)

Roles of Src family kinase, Ras, and mTOR signaling in intestinal epithelial homeostasis and tumorigenesis
por: Matozaki, Takashi, et al.
Publicado: (2020)

Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis
por: Zheng, Kang, et al.
Publicado: (2023)

Barriers to horizontal cell transformation by extracellular vesicles containing oncogenic H-ras
por: Lee, Tae Hoon, et al.
Publicado: (2016)

Oncogenic Ras downregulates mdr1b expression through generation of reactive oxygen species
por: Jun, Semo, et al.
Publicado: (2020)

The role of RAS oncogenes in controlling epithelial mechanics
por: Nyga, Agata, et al.
Publicado: (2023)

Ras Downstream Effector GGCT Alleviates Oncogenic Stress
por: He, Zaoke, et al.
Publicado: (2019)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
por: Hubbard, Paul A., et al.
Publicado: (2014)

Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer
por: Siegfried, Zahava, et al.
Publicado: (2013)

Translating the Role of mTOR- and RAS-Associated Signalopathies in Autism Spectrum Disorder: Models, Mechanisms and Treatment
por: Vasic, Verica, et al.
Publicado: (2021)

ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma
por: Wang, Dong, et al.
Publicado: (2017)

Low Incidence of Point Mutation of c‐Ki‐ras and N‐ras Oncogenes in Human Hepatocellular Carcinoma
por: Tsuda, Hitoshi, et al.
Publicado: (1989)

Oncogenic Ras Downregulates Rac Activity, Which Leads to Increased Rho Activity and Epithelial–Mesenchymal Transition
por: Zondag, Gerben C.M., et al.
Publicado: (2000)

Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis
por: Chang, Zhe, et al.
Publicado: (2014)

ZEB1 and oncogenic Ras constitute a regulatory switch for stimulus‐dependent E‐cadherin downregulation
por: Otake, Shigeo, et al.
Publicado: (2020)

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer
por: Wang, Chunmei, et al.
Publicado: (2013)

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
por: Wang, Zhiyong, et al.
Publicado: (2014)

Ras oncogene mutations and survival in patients with lung cancer
por: Ferretti, G, et al.
Publicado: (2006)

Intercellular Transfer of Oncogenic H-Ras at the Immunological Synapse
por: Rechavi, Oded, et al.
Publicado: (2007)

Acute sensitivity of the oral mucosa to oncogenic K-ras
por: van der Weyden, Louise, et al.
Publicado: (2011)

Structure, signaling and the drug discovery of the Ras oncogene protein
por: Han, Chang Woo, et al.
Publicado: (2017)

Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity
por: Konstantinidou, Georgia, et al.
Publicado: (2020)

Small molecule inhibitors of RAS proteins with oncogenic mutations
por: Orgován, Zoltán, et al.
Publicado: (2020)

ZNF768 links oncogenic RAS to cellular senescence
por: Villot, Romain, et al.
Publicado: (2021)

Alternative polyadenylation is a determinant of oncogenic Ras function
por: Subramanian, Aishwarya, et al.
Publicado: (2021)

Eliminating oncogenic RAS: back to the future at the drawing board
por: Steffen, Candy Laura, et al.
Publicado: (2023)

Mechanism-Based Redesign of GAP to Activate Oncogenic Ras
por: Berta, Dénes, et al.
Publicado: (2023)

Oncogene Ras/Phosphatidylinositol 3-Kinase Signaling Targets Histone H3 Acetylation at Lysine 56
por: Liu, Yan, et al.
Publicado: (2012)

Molecular Analysis of Oncogenes, ras Family Genes (N‐ras, K‐ras, H‐ras), myc Family Genes (c‐myc, N‐myc) and mdm2 in Natural Killer Cell Neoplasms
por: Sugimoto, Kei‐ji, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_i202nk727l3688j188901n2sj2